[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549432":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":11,"locations":31,"responsibleParty":214,"collaborators":11,"id":216,"slug":11,"hasResults":217,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":11,"eligibilityCriteria":221,"healthyVolunteers":217,"sex":222,"minAge":223,"maxAge":11,"enrollmentInfo":224,"targetDuration":11,"studyType":227,"phases":228,"briefSummary":230,"conditions":231,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},{"fullName":5,"class":6},"Opna Bio LLC","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose escalation monotherapy","EXPERIMENTAL",null,[13],"Drug: OPN-6602",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose escalation in combo with dexamethasone",[13,17],"Drug: Dexamethasone",{"label":19,"type":10,"description":11,"interventionNames":20},"Dose expansion",[13],[22,27],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","OPN-6602","orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily",[15,9,19],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Dexamethasone","Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle",[15],[32,51,66,80,95,110,125,140,154,169,184,199],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Banner MD Anderson","RECRUITING","Gilbert","Arizona","85234","United States",{"type":40,"coordinates":41},"Point",[42,43],-111.78903,33.35283,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":49,"phoneExt":11,"email":50},"Brett Post","CONTACT","480-256-3116","brett.post@bannerhealth.com",{"facility":52,"status":34,"city":53,"state":54,"zip":55,"country":38,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"UC San Diego Moores Cancer Center","La Jolla","California","92093-0698",{"type":40,"coordinates":57},[58,59],-117.2742,32.84727,{"lat":59,"lon":58},[62],{"name":63,"role":48,"phone":64,"phoneExt":11,"email":65},"Rebecca Jimenez","858-822-5377","rejimenez@health.ucsd.edu",{"facility":67,"status":34,"city":68,"state":54,"zip":69,"country":38,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Stanford Cancer Institute","Stanford","94305",{"type":40,"coordinates":71},[72,73],-122.16608,37.42411,{"lat":73,"lon":72},[76],{"name":77,"role":48,"phone":78,"phoneExt":11,"email":79},"Caitlyn Minas","650-723-0646","cminas@stanford.edu",{"facility":81,"status":34,"city":82,"state":83,"zip":84,"country":38,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Emory Winchip Cancer Center","Atlanta","Georgia","30322",{"type":40,"coordinates":86},[87,88],-84.38798,33.749,{"lat":88,"lon":87},[91],{"name":92,"role":48,"phone":93,"phoneExt":11,"email":94},"Megan Marshall","404-778-5204","megan.marshall@emory.edu",{"facility":96,"status":34,"city":97,"state":98,"zip":99,"country":38,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"University of Kansas Clinical Research Center","Westwood","Kansas","66205",{"type":40,"coordinates":101},[102,103],-94.6169,39.04056,{"lat":103,"lon":102},[106],{"name":107,"role":48,"phone":108,"phoneExt":11,"email":109},"Nurse Navigation","913-945-7552","CTNurseNav@kumc.edu",{"facility":111,"status":34,"city":112,"state":113,"zip":114,"country":38,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":40,"coordinates":116},[117,118],-71.05977,42.35843,{"lat":118,"lon":117},[121],{"name":122,"role":48,"phone":123,"phoneExt":11,"email":124},"Yuxin Liu","877-422-3324","yuxin_liu@dfci.harvard.edu",{"facility":126,"status":34,"city":127,"state":128,"zip":129,"country":38,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":40,"coordinates":131},[132,133],-83.04575,42.33143,{"lat":133,"lon":132},[136],{"name":137,"role":48,"phone":138,"phoneExt":11,"email":139},"Kate Staub","313-576-8736","staubk@karmanos.org",{"facility":141,"status":34,"city":142,"state":128,"zip":143,"country":38,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"START Midwest","Grand Rapids","49546",{"type":40,"coordinates":145},[146,147],-85.66809,42.96336,{"lat":147,"lon":146},[150],{"name":151,"role":48,"phone":152,"phoneExt":11,"email":153},"Julie Burns","616-954-5559","Julie.burns@startresearch.com",{"facility":155,"status":34,"city":156,"state":157,"zip":158,"country":38,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"University of Rochester Medical Center","Rochester","New York","14642",{"type":40,"coordinates":160},[161,162],-77.61556,43.15478,{"lat":162,"lon":161},[165],{"name":166,"role":48,"phone":167,"phoneExt":11,"email":168},"Liu","585-275-5823","wcicto@urmc.rochester.edu",{"facility":170,"status":34,"city":171,"state":172,"zip":173,"country":38,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"University of North Carolina Hospitals at Hillsborough","Chapel Hill","North Carolina","27599",{"type":40,"coordinates":175},[176,177],-79.05584,35.9132,{"lat":177,"lon":176},[180],{"name":181,"role":48,"phone":182,"phoneExt":11,"email":183},"Brice Messenger, CCRP","919-966-4432","brice_messenger@med.unc.edu",{"facility":185,"status":34,"city":186,"state":187,"zip":188,"country":38,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Huntsman Cancer Center Institute University of Utah","Salt Lake City","Utah","84112",{"type":40,"coordinates":190},[191,192],-111.89105,40.76078,{"lat":192,"lon":191},[195],{"name":196,"role":48,"phone":197,"phoneExt":11,"email":198},"Collind Boyington","801-587-4779","collind.boyington@hci.utah.edu",{"facility":200,"status":34,"city":201,"state":202,"zip":203,"country":38,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":40,"coordinates":205},[206,207],-122.33207,47.60621,{"lat":207,"lon":206},[210],{"name":211,"role":48,"phone":212,"phoneExt":11,"email":213},"Danai Dima","855-557-0555","ddima@fredhutch.org",{"type":215,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100549432",false,"NCT06433947","Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and\u002For Refractory Multiple Myeloma","A Phase 1b, Dose Escalation\u002FDose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and\u002For Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Confirmed diagnosis of multiple myeloma (MM)\n* Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody and not a candidate for or intolerant to established therapy known to provide clinical benefit\n* Adequate hematologic, renal, liver, cardiac function\n\nExclusion Criteria:\n\n* Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, Waldenström's macroglobulinemia, or IgM myeloma\n* Active plasma cell leukemia\n* Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS syndrome)\n* Prior Stevens Johnson syndrome\n* Localized radiation therapy to disease site(s) within 2 weeks of the first dose\n* Prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within \\\u003C90 days of the first dose of study drug\n* Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of first dose of study drug; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded.\n* Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug\n* Concomitant high-dose corticosteroids (except subjects on chronic steroids given for disorders other than myeloma)\n* Known central nervous system involvement by multiple myeloma\n* Active known second malignancy with exception of adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; adequately treated Stage 1 cancer from which the subject is currently in remission and has been in remission for ≥2 years; low-risk prostate cancer with a Gleason score \\\u003C7 and a PSA level \\\u003C10 ng\u002FmL; any other cancer from which the subject has been disease-free for ≥3 years\n* Ongoing systemic infection requiring parenteral treatment\n* Poorly controlled Type 2 diabetes","ALL","18 Years",{"count":225,"type":226},130,"ESTIMATED","INTERVENTIONAL",[229],"PHASE1","Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and\u002For refractory MM.",[232,233],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma","2026-05-15",{"date":236,"type":237},"2026-05-19","ACTUAL",{"date":239,"type":237},"2024-08-22",{"date":241,"type":226},"2026-07",{"name":5,"class":6},12]